Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma (brain cancer), saying that it was not able to adequately address the concerns of the CHMP regarding the quality and efficacy of the medicine within the required time schedule.
Oncoscience is the European licensee of nimotuzumab, a humanised monoclonal antibody, from YM BioSciences' subsidiary CIMYM BioSciences.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?